View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
August 13, 2012

Genentech reports Phase III AVAglio study results

Genentech, a member of Roche Group, has reported that the Phase III AVAglio study of Avastin (bevacizumab) met its co-primary endpoint of a significant improvement in progression-free survival (PFS).

Genentech, a member of Roche Group, has reported that the Phase III AVAglio study of Avastin (bevacizumab) met its co-primary endpoint of a significant improvement in progression-free survival (PFS).

Avastin is designed for the treatment of adults with glioblastoma (cancer of the glial cells) who have progressive disease following prior therapy.

Avastin, a biologic antibody, directly binds to the VEGF protein, which plays a critical role throughout the lifecycle of the tumor to develop and maintain blood vessels.

The double-blind, placebo controlled, randomised Phase III trial is designed to assess the safety and efficacy of Avastin in combination with radiation and temozolomide chemotherapy, following surgery or biopsy in patients with newly diagnosed glioblastoma.

The secondary endpoints of the study include one and two-year survival rates.

The study results demonstrated that Avastin, in combination with radiation and temozolomide chemotherapy, extended the time patients with glioblastoma lived without the disease getting worse.

Genentech chief medical officer and head of global product development Dr Hal Barron said; "This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy."

No new safety findings were observed in the AVAglio study, and adverse events were consistent with those seen in previous trials of Avastin across tumor types for approved indications, according to the company.

The data for final overall survival, the other co-primary endpoint, is expected to be announced in 2013.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU